Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODX NASDAQ:FEMY NASDAQ:NDRA NASDAQ:OSRH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$0.34-0.8%$0.29$0.23▼$1.40$13.14M0.781.01 million shs599,700 shsFEMYFemasys$0.39+6.8%$0.71$0.31▼$1.80$12.78M-2.64623,135 shs1.22 million shsNDRAENDRA Life Sciences$4.74+2.8%$5.34$2.90▼$22.68$3.57M-0.14650,490 shs34,963 shsOSRHOSR$0.62+1.7%$0.81$0.45▼$13.40$13.38M1.513.55 million shs199,837 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics+12.20%+11.36%+35.59%+24.73%-72.70%FEMYFemasys+2.26%-0.81%-49.73%-58.73%-68.09%NDRAENDRA Life Sciences+6.59%+6.34%+8.37%+31.30%-48.15%OSRHOSR+2.81%+2.90%+8.54%-56.74%+60,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$0.34-0.8%$0.29$0.23▼$1.40$13.14M0.781.01 million shs599,700 shsFEMYFemasys$0.39+6.8%$0.71$0.31▼$1.80$12.78M-2.64623,135 shs1.22 million shsNDRAENDRA Life Sciences$4.74+2.8%$5.34$2.90▼$22.68$3.57M-0.14650,490 shs34,963 shsOSRHOSR$0.62+1.7%$0.81$0.45▼$13.40$13.38M1.513.55 million shs199,837 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics+12.20%+11.36%+35.59%+24.73%-72.70%FEMYFemasys+2.26%-0.81%-49.73%-58.73%-68.09%NDRAENDRA Life Sciences+6.59%+6.34%+8.37%+31.30%-48.15%OSRHOSR+2.81%+2.90%+8.54%-56.74%+60,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 3.00Buy$5.501,512.43% UpsideFEMYFemasys 3.00Buy$7.331,770.27% UpsideNDRAENDRA Life Sciences 3.00Buy$50.00954.85% UpsideOSRHOSR 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NDRA, OSRH, FEMY, and CODX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025CODXCo-DiagnosticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.006/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$3.91M3.36N/AN/A$1.70 per share0.20FEMYFemasys$1.63M7.84N/AN/A$0.10 per share3.92NDRAENDRA Life SciencesN/AN/AN/AN/A$4.77 per shareN/AOSRHOSRN/AN/AN/AN/A($3.87) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$37.64M-$1.15N/AN/AN/A-3,588.33%-69.49%-60.49%11/6/2025 (Estimated)FEMYFemasys-$18.82M-$0.86N/AN/AN/A-1,113.72%-713.74%-152.60%11/11/2025 (Estimated)NDRAENDRA Life Sciences-$11.51M-$33.89N/AN/AN/AN/A-194.14%-127.89%11/21/2025 (Estimated)OSRHOSR-$2.41MN/A0.00∞N/AN/A-12.19%-8.18%N/ALatest NDRA, OSRH, FEMY, and CODX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CODXCo-Diagnostics-$0.25-$0.23+$0.02-$0.23$0.30 million$0.16 million8/14/2025Q2 2025NDRAENDRA Life Sciences-$2.27-$1.71+$0.56-$1.71N/AN/A8/14/2025Q2 2025OSRHOSRN/A$0.02N/A$0.02N/A$1.14 million8/8/2025Q2 2025FEMYFemasys-$0.18-$0.16+$0.02-$0.16$0.80 million$0.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A4.123.83FEMYFemasys0.030.890.41NDRAENDRA Life SciencesN/A3.213.21OSRHOSRN/A0.180.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%FEMYFemasys65.27%NDRAENDRA Life Sciences1.19%OSRHOSR55.30%Insider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics8.40%FEMYFemasys11.54%NDRAENDRA Life Sciences0.04%OSRHOSR60.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics10038.52 million35.29 millionOptionableFEMYFemasys3032.58 million28.82 millionNot OptionableNDRAENDRA Life Sciences20753,000753,000Not OptionableOSRHOSRN/A21.58 million8.50 millionN/ANDRA, OSRH, FEMY, and CODX HeadlinesRecent News About These CompaniesOSR Holdings receives non-compliance letter from NasdaqSeptember 10 at 2:00 AM | msn.comOSR Holdings receives Nasdaq notice for minimum bid price non-complianceSeptember 9 at 7:59 PM | msn.comOSR Holdings Faces Nasdaq Non-Compliance NoticeSeptember 9 at 5:31 PM | tipranks.comOSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading ActivitySeptember 9 at 5:30 PM | prnewswire.comOSR Holdings Faces Lawsuit from Chardan Capital MarketsSeptember 9 at 6:50 AM | tipranks.comOSR Holdings Amends Note Purchase AgreementAugust 20, 2025 | tipranks.comLatest OSR Holdings Stock News | NASDAQ:OSRH | BenzingaAugust 9, 2025 | benzinga.comOSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025August 1, 2025 | prnewswire.comOSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share ...August 1, 2025 | morningstar.comMOSR Holdings Inc.: OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange StructureAugust 1, 2025 | finanznachrichten.deOSR Holdings Reveals Update on Woori IO Deal and Share ExchangeAugust 1, 2025 | msn.comOSR Holdings Provides Transparency Update on Equity Financing InstrumentsJuly 31, 2025 | prnewswire.comOSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange StructureJuly 30, 2025 | prnewswire.comOSR Holdings to acquire South Korea’s medical device company Woori IOJuly 28, 2025 | finance.yahoo.comOSR Holdings enters term sheet to acquire Woori IO (OSRH:NASDAQ)July 25, 2025 | seekingalpha.comOSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in ...July 25, 2025 | seekingalpha.comOSR Holdings signs term sheet to acquire noninvasive glucose tech firmJuly 25, 2025 | investing.comOSR Holdings signs term sheet to acquire South Korea-based noninvasive glucose monitoring technology company, Woori IOJuly 25, 2025 | pharmabiz.comPOSR Holdings enters term sheet to acquire Woori IOJuly 24, 2025 | msn.comOSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring TechnologyJuly 24, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNDRA, OSRH, FEMY, and CODX Company DescriptionsCo-Diagnostics NASDAQ:CODX$0.34 0.00 (-0.84%) Closing price 04:00 PM EasternExtended Trading$0.35 +0.01 (+2.61%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Femasys NASDAQ:FEMY$0.39 +0.03 (+6.84%) Closing price 04:00 PM EasternExtended Trading$0.39 0.00 (-0.54%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.ENDRA Life Sciences NASDAQ:NDRA$4.74 +0.13 (+2.82%) Closing price 03:59 PM EasternExtended Trading$4.72 -0.02 (-0.42%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.OSR NASDAQ:OSRH$0.62 +0.01 (+1.66%) As of 03:59 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
